Clinical trials: Mild Hypertension
Hypertension
A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension
A Randomized, Double-Blind, Multicenter, phase III Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan (BR-A-657·K) 30mg Compared to Placebo in Patients with Mild to Moderate Essential Hypertension
- Trial name
- fimasartan (NCT01672476)
- Testing
- Valsartan, Fimasartan
- Where
- South Korea
- Volunteers
- 293 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
COREG MR Versus TOPROL-XL On The Lipid Profile Of Normolipidemic Or Mildly Dyslipidemic Patients With Hypertension
This study was designed to determine whether treatment with COREG MR is more effective at maintaining a better lipid profile than treatment with TOPROL-XL for hypertension.
- Trial name
- NCT00273052
- Testing
- Carvedilol Phosphate modified release formulation, metoprolol succinate
- Where
- 120 sites in United States, Canada and 1 more
- Volunteers
- 514 people
- Sponsor
- GlaxoSmithKline
Hypertension
Effects of Telmisartan by Ambulatory Blood Pressure Monitoring (ABPM) in Chinese Patients With Mild to Moderate Essential Hypertension
To assess the trough/peak ratio of 40 mg Telmisartan tablet by ambulatory blood pressure monitoring in Chinese patients with mild to moderate essential hypertension
- Trial name
- NCT02206659
- Testing
- Telmisartan
- Volunteers
- 20 people
- Sponsor
- Boehringer Ingelheim
High Blood Pressure
Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension
The purpose of this study is to investigate the efficacy and safety of Bunazosin with Valsartin compared to Doxazosin with Valsartin for patients with mild to moderate essential hypertension accompanied by metabolic syndrome.
- Trial name
- NCT00130156
- Testing
- Bunazosin, Doxazosin, Valsartin
- Where
- Taiwan
- Volunteers
- 93 people
- Sponsor
- Eisai Inc.
Hypertension
Efficacy and Safety of Aliskiren in Patients With Mild to Moderate Hypertension During Exercise
This study compared the blunting effect of aliskiren and valsartan monotherapies on exercise-induced rises in systolic blood pressure in patients with mild to moderate essential hypertension.
- Trial name
- NCT00819767
- Testing
- Aliskiren, Valsartan
- Where
- 8 sites in Czechia, Hungary and 2 more
- Volunteers
- 68 people
- Sponsor
- Novartis
Prehypertension
Effect and Safety of Marealis RPC (Refined Peptide Concentrate) in Mild or Moderate Hypertensive Subjects
Hypertension is an important risk factor of cardiovascular (CVD) and renal diseases. Epidemiological studies show that there is a direct relationship between blood pressure and CVD, and cardiovascular mortality increases…
- Trial name
- NCT01974570
- Testing
- Marealis refined peptide concentrate
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- KGK Science Inc.
Hypertension
Efficacy of Irbesartan/Hydrochlorothiazide Versus Valsartan/Hydrochlorothiazide in Mild to Moderate Hypertension
The primary objective is to compare the efficacy of irbesartan/hydrochlorothiazide 300/25mg against valsartan/hydrochlorothiazide 160/25mg in reducing mean systolic blood pressure (SBP) as measured by home blood pressure…
- Trial name
- COSIMA2 (NCT00500604)
- Testing
- Irbesartan/hydrochlorothiazide, Valsartan/hydrochlorothiazide, Hydrochlorothiazide
- Where
- 14 sites in Egypt, Hong Kong and 12 more
- Volunteers
- 1,617 people
- Sponsor
- Sanofi
Open Angle Glaucoma
Open Label, Sequential-dose Study of PA5108 Latanoprost FA SR Ocular Implant for Mild-moderate Glaucoma
This is a multi-centre, open label, interventional, comparative, phase I study to identify a safe and efficacious dose (within the range of 14.7mcg to 35.5 mcg) of PA5108 (PolyActiva product code) Latanoprost free acid (FA)…
- Trial name
- NCT04060758
- Testing
- PA5108 Latanoprost FA SR Ocular Implant
- Where
- 9 sites in Australia, New Zealand
- Volunteers
- 37 people
- Sponsor
- PolyActiva Pty Ltd
Essential Hypertension
Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension
Efficacy, tolerability and safety of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension
- Trial name
- OSCAR (NCT00139698)
- Testing
- olmesartan alone or in combination with hydrochlorothiazide
- Where
- 32 sites in Colombia, Ecuador and 8 more
- Volunteers
- 410 people
- Sponsor
- Pfizer
Essential Hypertension
NW Roselle in Grade 1 Essential Hypertension: Phase III Clinical Trial
In this Phase III clinical trial, researchers evaluate the efficacy and safety of NW Roselle®, a powdered medicinal product developed by Natural Wellness.
- Trial name
- NCT06141200
- Testing
- NW Roselle, Captopril 25Mg Tab
- Volunteers
- 286 people
- Sponsor
- Natural Wellness Egypt
Hypertension
I SAVE - Irbesartan in Mild to Moderate Hypertensive Patients
To evaluate control rate of Blood Pressure ≤ 140/90 mm Hg in non-diabetic patients, and ≤ 130/80 mm Hg in diabetic patients. To determine percentage of patients achieving blood pressure control according to their profile (naïve…
- Trial name
- NCT00335673
- Testing
- Irbesartan (Aprovel)
- Where
- Egypt
- Volunteers
- 1,630 people
- Sponsor
- Sanofi
Glaucoma, Cataract
Observational Study to Evaluate Long Term Outcomes for Ocular Hypertension and Glaucoma Patients Treated With the SpyGlass Bimatoprost Implant System / IOL Combination
The goal of this clinical trial is to further observe and learn if the SpyGlass Pharma Bimatoprost Implant System / IOL Combination works to treat cataracts and either ocular hypertension or glaucoma.
- Conditions
- Glaucoma, Cataract, Ocular Hypertension
- Trial name
- NCT07154810
- Where
- Honduras
- Volunteers
- 23 people
- Sponsor
- SpyGlass Pharma, Inc.
Hypertension, Impaired Glucose Tolerance
Evaluation of Soluble Epoxide Hydrolase (s-EH) Inhibitor in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance
The purpose of this study is to determine the safety and efficacy of AR9281, a novel s-EH enzyme inhibitor, in improving glucose metabolism and blood pressure in patients with impaired glucose tolerance and mild to moderate…
- Trial name
- NCT00847899
- Testing
- AR9281
- Where
- 30 sites in United States
- Volunteers
- 150 people
- Sponsor
- Arete Therapeutics
Mild to Moderate Hypertension and Elevated Low-Density Lipoprotein Cholesterol
A Study of BEBT-701 in Patients With Mild to Moderate Hypertension and Elevated Low-Density Lipoprotein Cholesterol（LDL-C）
This Phase I/II clinical trial is designed to evaluate, through a single-dose Phase I segment and a multiple-dose Phase II segment, the safety/tolerability, pharmacokinetic (PK) profile, and pharmacodynamic (PD) characteristics…
- Trial name
- NCT07368608
- Testing
- BEBT-701 Injection
- Where
- China
- Volunteers
- 340 people
- Sponsor
- BeBetter Med Inc
Hypertension
PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN
Demonstrate that telmisartan 80mg was at least as effective and possibly superior to ramipril 5mg \& 10mg in lowering mean ambulatory DBP and SBP during the last 6 hrs of the 24-hr dosing interval in mild-to-moderate…
- Trial name
- NCT00274599
- Testing
- Telmisartan, Ramipril
- Where
- 74 sites in United States, Canada
- Volunteers
- 812 people
- Sponsor
- Boehringer Ingelheim
Chronic Kidney Disease, Arterial Hypertension
A Study to Learn About the Safety of BAY3283142 in People With Mild to Moderate High Blood Pressure
In this study, researchers want to learn about the safety of BAY3283142 after a single dose and multiple doses in participants with mild to moderate high blood pressure.
- Trial name
- NCT06428825
- Testing
- BAY3283142
- Where
- 2 sites in Germany
- Volunteers
- 75 people
- Sponsor
- Bayer
Hypertension
Effectiveness and Safety of Combination of Nebivolol and Amlodipine in Hypertensive Patients Versus Each Monotherapy
Study to assess the anti-hypertensive efficacy and safety of the extemporaneous combination of Nebivolol 5 mg in combination with Amlodipine 5 mg or AML 10 mg in lowering the sitting diastolic BP after 8 weeks of treatment…
- Trial name
- Botticelli (NCT05513937)
- Testing
- Nebivolol, Amlodipine
- Where
- Bulgaria
- Volunteers
- 301 people
- Sponsor
- Menarini International Operations Luxembourg SA
Hypertension
Phase IIa Safety and Efficacy Study of SPP635 in Mild to Moderate Hypertension
This study is conducted to investigate the effect of the oral renin inhibitor SPP635 on blood pressure in patients with mild to moderate hypertension.
- Trial name
- NCT00376636
- Testing
- SPP635 (drug)
- Where
- Germany
- Volunteers
- 35 people
- Sponsor
- Speedel Pharma Ltd.
Essential Hypertension ( Mild to Moderate)
Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension
This study will assess the efficacy of an aliskiren based treatment regimen in reaching blood pressure (BP) target in patients with mild to moderate hypertension.
- Trial name
- NCT00765947
- Testing
- Aliskiren, Hydrochlorothiazide, Amlodipine
- Where
- 4 sites in France, Hungary and 2 more
- Volunteers
- 256 people
- Sponsor
- Novartis
Hypertension
A Study Evaluating the Effects of Nebivolol on Blood Pressure in Hypertensive Patients
The purpose of this study is to evaluate the effects of various doses of nebivolol in patients with mild to moderate hypertension.
- Trial name
- NCT00200460
- Testing
- Nebivolol
- Where
- United States
- Volunteers
- 825 people
- Sponsor
- Mylan Bertek Pharmaceuticals